Literature DB >> 2128460

The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

J S Cameron1, G Frampton.   

Abstract

In recent years an association has been described between, on the one hand, an in vitro prolongation of phospholipid-dependent coagulation tests (the 'lupus anticoagulant') or the demonstration of antiphospholipid antibodies and, on the other, clinical events, particularly recurrent thrombosis (usually venous but sometimes arterial), thrombocytopenia, and also recurrent mid-term fetal loss. Other less well-documented associations with haemolytic anaemia, livedo reticularis, strokes and other neurological syndromes have been suggested. The antibodies are present temporarily in many infections, are usually of IgM isotype and thrombosis does not occur. However, they are persistently present and mainly of IgG isotype in a number of auto-immune disorders associated with thrombosis, in particular systemic lupus erythematosus, in which 50% of patients will show antibody of one isotype or another. The strongest association is with antinuclear factor-negative lupus and 'lupus-like' disorders in which a full diagnosis of classical lupus cannot be made. The clotting test abnormality and antiphospholipid antibodies may be found also in otherwise normal individuals suffering thrombosis or fetal loss--the so-called primary antiphospholipid syndrome. These data raise important questions for management, but many details are controversial despite a decade's work; this review examines the present position and outlines some of the difficulties, particularly from the point of view of nephrology and paediatrics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128460     DOI: 10.1007/bf00858647

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  160 in total

1.  The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors.

Authors:  J E MOORE; W B LUTZ
Journal:  J Chronic Dis       Date:  1955-03

2.  The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies.

Authors:  R A Fields; H Toubbeh; R P Searles; A D Bankhurst
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

3.  Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant.

Authors:  F De Wolf; L O Carreras; P Moerman; J Vermylen; A Van Assche; M Renaer
Journal:  Am J Obstet Gynecol       Date:  1982-04-01       Impact factor: 8.661

4.  Severe Guillain-Barré syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients.

Authors:  G Frampton; J B Winer; J S Cameron; R A Hughes
Journal:  J Neuroimmunol       Date:  1988-08       Impact factor: 3.478

5.  Anticardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  G Sturfelt; O Nived; R Norberg; R Thorstensson; K Krook
Journal:  Arthritis Rheum       Date:  1987-04

6.  Lupus nephritis: clinical and pathological correlation.

Authors:  B Leaker; K F Fairley; J Dowling; P Kincaid-Smith
Journal:  Q J Med       Date:  1987-02

7.  Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria.

Authors:  P Carroll; D Stafford; R S Schwartz; B D Stollar
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

8.  Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants.

Authors:  H I Glueck; K S Kant; M A Weiss; V E Pollak; M A Miller; M Coots
Journal:  Arch Intern Med       Date:  1985-08

9.  Polyreactive autoantibodies are nephritogenic in murine lupus nephritis.

Authors:  O G Pankewycz; P Migliorini; M P Madaio
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

10.  Anti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity.

Authors:  C B Colaço; G K Scadding; S Lockhart
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

View more
  4 in total

1.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

2.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

Review 3.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

4.  Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus.

Authors:  T Sitter; M Spannagl; H Schiffl
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.